Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib

Tracking the Evolution of Non–Small-Cell Lung Cancer

Mariam Jamal‐Hanjani, Gareth A. Wilson, Nicholas McGranahan et al. · New England Journal of Medicine · 2017 · 2.4K citations · Full text

Medicine, Genetics, Oncology +17

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu et al. · Cancer Discovery · 2014 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham et al. · JAMA Oncology · 2018 · 689 citations · Full text

Medicine, Oncology, Pharmacology +17

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Matthew J. Niederst, Lecia V. Sequist, John T. Poirier et al. · Nature Communications · 2015 · 633 citations · Full text

Medicine, Cancer Biology, Oncology +17

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

Collin M. Blakely, Thomas B.K. Watkins, Wei Wu et al. · Nature Genetics · 2017 · 578 citations

Medicine, Genetics, Oncology +16